C

Curia

End-to-end drug development and manufacturing

Stability Supervisor - Quality Control

Full-Time
$87k - $108.6k/yr
Senior
Bachelor's
Rensselaer, NY, USA
In Person

About the job

Requirements
  • A Bachelor's degree in Chemistry, Analytical Chemistry, or a related field.
  • At least 5 years of experience in a GMP or FLP environment working with chromatography, including HPLC, UPLC, or GC, and extensive method development and/or validation experience.
  • At least 2 years of supervisory experience.
  • Strong oral and written communication skills, including effective listening.
  • Demonstrated ability to effectively utilize team resources.
  • Expertise in cGMP, USP, EP, and FDA regulations.
  • Technical competence in the theory and interpretation of laboratory techniques.
  • Proficient use of computer software, including Microsoft Office Suite, Excel, Word, and other required software.
  • Strong organizational skills and the ability to multitask.
  • Proficiency in HPLC and GC method development and method validation, with extensive experience using multiple other analytical techniques and analytical equipment.
  • Prior experience and knowledge of FDA GMPs, including 21 CFR Parts 211, 820, and/or 600, ISO 9001 and 13485, and ICH Stability guidelines.
  • Ability to pass a background check and drug screen.
  • Ability to pass an occupational health screening if required.
  • Ability to frequently reach with the hands and arms; occasionally climb, balance, stoop, kneel, crouch, or crawl; and occasionally lift or move up to 50 pounds.
  • Ability to work safely with potential exposure to fumes, airborne particles, toxic or caustic chemicals, wet or humid conditions, moving mechanical parts, high or precarious places, outdoor weather, and electrical shock risks, using required personal protective equipment.
  • Familiarity with applicable Resource Conservation and Recovery Act training requirements and hazardous-waste labeling, containment, compatibility, storage, container limits, integrity, and disposal requirements.
Responsibilities
  • Oversee the day-to-day functions of the Quality Control Stability department and manage the Quality Control Chemists focused on stability testing.
  • Manage the Quality Control Stability Team's performance of analytical testing for stability samples and incoming, in-process, and final products.
  • Ensure analytical chemistry functions comply with company and governmental safety and quality standards and that experimental documentation is complete and timely.
  • Supervise scientists, including their motivation, education, efficiency, performance management, and productivity.
  • Ensure laboratory operations are conducted safely and follow the Chemical Hygiene Plan and safety rules.
  • Maintain compliance with regulations and strict adherence to standard operating procedures and cGMPs.
  • Organize workloads and coordinate activities across multiple concurrent projects according to objectives, timelines, and deadlines.
  • Conduct investigations of out-of-specification results, deviations, change control management, and corrective and preventive actions.
  • Supervise and perform pharmaceutical analysis supporting drug product manufacturing.
  • Perform routine analytical chemistry assays of stability samples, with occasional testing of raw materials, in-process samples, finished active pharmaceutical ingredients, and special projects.
  • Work outside normal business hours when needed.
  • Generate hazardous waste for treatment, storage, and disposal.

About the company

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$132M

Headquarters

Albany, New York

Founded

1991

Get referred to Curia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Curia expanded Glasgow sterile drug product capacity in March 2026.
  • Curia completed a $4 million sterile API upgrade in Valladolid in October 2025.
  • Curia won a 2025 CDMO Leadership Award in Global Biologics.

What critics are saying

  • Curia is closing Burlington in 2026 and cutting 81 jobs.
  • Curia is working on an out-of-court restructuring with private credit lenders.
  • Asset sales like Pace’s New Jersey lab purchase signal continued portfolio shrinkage.

What makes Curia unique

  • Curia spans discovery through commercial manufacturing across small molecules and biologics.
  • Curia manufactures mRNA and self-replicating RNA, including Replicate Bioscience’s RBI-4000.
  • Curia runs 20+ global sites with sterile fill-finish and cell-line development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

↑ 0%

1 year growth

↑ 0%

2 year growth

↑ 0%
Carlyle
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

Pakistan Press International
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.